Ocular surface defects represent one of the most common causes of impaired vision or even blindness. For treatment, keratoplasty represents the first choice. However, if corneal defects are more extensive and associated with a limbal stem cell (LSC) deficiency, corneal transplantation is not a sufficient therapeutic procedure and only viable approach to treatment is the transplantation of LSCs. When the LSC deficiency is a bilateral disorder, autologous LSCs are not available. The use of allogeneic LSCs requires strong immunosuppression, which leads to side-effects, and the treatment is not always effective. The alternative and perspective approach to the treatment of severe ocular surface injuries and LSC deficiency is offered by the transplantation of autologous mesenchymal stem cells (MSCs). These cells can be obtained from the bone marrow or adipose tissue of the particular patient, grow well in vitro and can be transferred, using an appropriate scaffold, onto the damaged ocular surface. Here they exert beneficial effects by possible direct differentiation into corneal epithelial cells, by immunomodulatory effects and by the production of numerous trophic and growth factors. Recent experiments utilizing the therapeutic properties of MSCs in animal models with a mechanically or chemically injured ocular surface have yielded promising results and demonstrated significant corneal regeneration, improved corneal transparency and a rapid healing process associated with the restoration of vision. The use of autologous MSCs thus represents a promising therapeutic approach and offers hope for patients with severe ocular surface injuries and LSC deficiency.

Department of Transplantation Immunology Institute of Experimental Medicine Academy of Sciences of the Czech Republic Videnska 1083 14220 Prague 4 Czech Republic

Zobrazit více v PubMed

Invest Ophthalmol Vis Sci. 2012 Jan 31;53(1):513-20 PubMed

PLoS One. 2012;7(2):e30842 PubMed

Invest Ophthalmol Vis Sci. 1991 Jan;32(1):96-105 PubMed

Stem Cells. 2006 Feb;24(2):315-21 PubMed

Transpl Immunol. 2011 Apr 15;24(3):189-94 PubMed

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5279-86 PubMed

Stem Cells. 2007 May;25(5):1145-55 PubMed

Lancet. 1997 Apr 5;349(9057):990-3 PubMed

J Cell Mol Med. 2012 May;16(5):1114-24 PubMed

Invest Ophthalmol Vis Sci. 2002 Mar;43(3):647-55 PubMed

Stem Cells. 2006 Feb;24(2):426-33 PubMed

Biomacromolecules. 2009 Sep 14;10(9):2609-18 PubMed

J Pathol. 2009 Jan;217(2):217-28 PubMed

Graefes Arch Clin Exp Ophthalmol. 2012 Mar;250(3):455-7 PubMed

J Intern Med. 2007 Nov;262(5):509-25 PubMed

Invest Ophthalmol Vis Sci. 2012 Jun 14;53(7):3638-44 PubMed

Stem Cell Rev Rep. 2012 Jun;8(2):375-92 PubMed

Biomaterials. 2007 Jan;28(2):316-25 PubMed

Ophthalmology. 1996 Jan;103(1):29-36 PubMed

J Biomed Mater Res B Appl Biomater. 2008 Oct;87(1):222-8 PubMed

Br J Ophthalmol. 2007 Apr;91(4):459-64 PubMed

Exp Eye Res. 2005 Sep;81(3):247-64 PubMed

Blood. 2005 Sep 1;106(5):1755-61 PubMed

Stem Cells. 2010 Dec;28(12):2172-81 PubMed

N Engl J Med. 2004 Sep 16;351(12):1187-96 PubMed

Br J Ophthalmol. 2004 Oct;88(10):1280-4 PubMed

J Immunol. 2010 Feb 15;184(4):2124-9 PubMed

Exp Eye Res. 2012 Sep;102:44-9 PubMed

Invest Ophthalmol Vis Sci. 2011 Mar 10;52(3):1252-60 PubMed

Am J Ophthalmol. 2008 Aug;146(2):251-259 PubMed

Biol Blood Marrow Transplant. 2005 May;11(5):389-98 PubMed

Ophthalmology. 2009 May;116(5):856-63 PubMed

Stem Cells Dev. 2012 Apr 10;21(6):901-10 PubMed

Cell Prolif. 2009 Oct;42(5):587-94 PubMed

Am J Ophthalmol. 2011 Nov;152(5):739-47.e1 PubMed

Blood. 2002 May 15;99(10):3838-43 PubMed

Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1113-29 PubMed

Arthritis Rheum. 2007 Apr;56(4):1175-86 PubMed

Surv Ophthalmol. 2007 Sep-Oct;52(5):483-502 PubMed

J Pathol. 2002 Jul;197(4):479-91 PubMed

Stem Cells. 2008 Feb;26(2):570-9 PubMed

PLoS One. 2010 May 19;5(5):e10707 PubMed

Mol Vis. 2012;18:161-73 PubMed

Cytotherapy. 2006;8(6):559-61 PubMed

J Immunol. 2008 Feb 15;180(4):2581-7 PubMed

Dev Ophthalmol. 2010;45:57-70 PubMed

Mol Vis. 2009;15:99-107 PubMed

Lancet. 2004 May 1;363(9419):1439-41 PubMed

Stem Cells. 2007 Oct;25(10):2648-59 PubMed

Fibrogenesis Tissue Repair. 2011 Sep 08;4:20 PubMed

Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1408-14 PubMed

Mol Ther. 2012 Nov;20(11):2143-52 PubMed

Ophthalmic Res. 2013;49(3):115-21 PubMed

Cornea. 2000 Jul;19(4):443-50 PubMed

Mol Vis. 2008 Jun 05;14:1064-70 PubMed

Stem Cells. 2006 Nov;24(11):2391-7 PubMed

J Immunol. 2010 Jul 1;185(1):302-12 PubMed

Cytotherapy. 2006;8(4):315-7 PubMed

Stem Cell Rev Rep. 2011 Jun;7(2):256-68 PubMed

Stem Cells. 2009 Mar;27(3):642-52 PubMed

Bull World Health Organ. 2001;79(3):214-21 PubMed

Stem Cells. 2007 Nov;25(11):2896-902 PubMed

Exp Hematol. 2002 Jan;30(1):42-8 PubMed

J Cell Mol Med. 2007 May-Jun;11(3):502-8 PubMed

Science. 1999 Apr 2;284(5411):143-7 PubMed

Cell Res. 2007 Mar;17(3):240-8 PubMed

Mol Vis. 2011;17:2102-17 PubMed

Stem Cells. 2011 Oct;29(10):1572-9 PubMed

J Cell Sci. 1998 Oct;111 ( Pt 19):2867-75 PubMed

Nature. 2008 Nov 13;456(7219):250-4 PubMed

Ophthalmic Res. 2012;48(2):82-88 PubMed

Transplantation. 2001 Nov 15;72(9):1478-85 PubMed

Cornea. 2003 Oct;22(7 Suppl):S75-80 PubMed

Recent Pat Nanotechnol. 2009;3(1):21-31 PubMed

Clin Exp Ophthalmol. 2012 Apr;40(3):255-67 PubMed

J Am Chem Soc. 2003 Jun 18;125(24):7146-7 PubMed

Cell Tissue Kinet. 1970 Oct;3(4):393-403 PubMed

N Engl J Med. 2010 Jul 8;363(2):147-55 PubMed

Int J Nanomedicine. 2012;7:5315-25 PubMed

Opt Express. 2008 Jul 7;16(14):10815-22 PubMed

Stem Cells. 2008 Apr;26(4):1047-55 PubMed

Ophthalmology. 1989 May;96(5):709-22; discussion 722-3 PubMed

Mol Biol Rep. 1996;23(1):47-58 PubMed

Development. 2001 Dec;128(24):5181-8 PubMed

Br J Ophthalmol. 1999 Apr;83(4):414-9 PubMed

Ophthalmology. 2002 Jul;109(7):1285-90 PubMed

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16875-80 PubMed

Methods Mol Biol. 2013;1014:187-99 PubMed

Exp Eye Res. 2010 Feb;90(2):188-95 PubMed

Zhonghua Yan Ke Za Zhi. 2010 Aug;46(8):719-24 PubMed

Acta Ophthalmol. 2011 Dec;89(8):741-8 PubMed

Regen Med. 2012 Mar;7(2):167-78 PubMed

Stem Cell Rev Rep. 2011 Nov;7(4):935-47 PubMed

Surv Ophthalmol. 2000 Mar-Apr;44(5):415-25 PubMed

Am J Ophthalmol. 2012 Apr;153(4):643-50, 650.e1-2 PubMed

World J Stem Cells. 2010 Aug 26;2(4):81-92 PubMed

N Engl J Med. 1999 Jun 3;340(22):1697-703 PubMed

Int J Health Sci (Qassim). 2013 Jan;7(1):67-74 PubMed

Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):186-91 PubMed

J Control Release. 2011 Dec 20;156(3):406-12 PubMed

Cell Transplant. 2010;19(10):1281-90 PubMed

Mol Vis. 2012;18:2087-95 PubMed

Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1149-56 PubMed

Stem Cells Dev. 2012 Dec 10;21(18):3341-50 PubMed

Arch Ophthalmol. 2006 Dec;124(12):1734-40 PubMed

Mol Vis. 2010 Jul 14;16:1304-16 PubMed

Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials

The Immunomodulatory Potential of Mesenchymal Stem Cells in a Retinal Inflammatory Environment

A Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells and Limbal Epithelial Stem Cells for Ocular Surface Reconstruction